Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin’s regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and protects against oxidative stress. It also provides Baolift that improves muscle tone and facial complexion; Elaya Renova that boosts hair tensegrity; Kannabia Sense, a prebiotic treatment that stimulates the skin microbiota to produce an in-situ postbiotic cocktail; Quora Noni to avoid the attack of skin harmful bacteria; Centella Reversa for facial complexion improvement; and Arabian Cotton to protect and repair cell structures against sun damage. In addition, the company offers Photobiome, a prebiotic active that fights the skin photoageing process; Nectaria Lithops, an active ingredient that biophysically optimizes the skin microenvironment and vitamin D levels; Olea Vitae, a cellular oil against ageing; Turmeria Zen for skin hydration and wrinkles on stressed profiles; and Sensia Carota, a plant-based active that protects and prevents from the damage on sensitive and sensitized skins. Further, it provides technology solutions, such as plasma rich in cell factors; phyto-peptidic, phyto-lipidic, and phyto-glucidic fractions; and phyto-cell fusions, as well as Vytrus TV to create an audiovisual space with added value for cosmetic formulation. The company exports its products. Vytrus Biotech, S.A. was incorporated in 2009 and is headquartered in Barcelona, Spain.
Metrics to compare | VYT | Sector Sector - Average of metrics from a broad group of related Industrials sector companies | Relationship RelationshipVYTPeersSector | |
|---|---|---|---|---|
P/E Ratio | 31.2x | 15.1x | 12.0x | |
PEG Ratio | - | −0.05 | 0.03 | |
Price/Book | 6.8x | 0.5x | 1.5x | |
Price / LTM Sales | 7.5x | 0.7x | 0.9x | |
Upside (Analyst Target) | −41.5% | 15.1% | 19.6% | |
Fair Value Upside | Unlock | 25.7% | 10.9% | Unlock |